We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vistin Pharma Asa | LSE:0RAM | London | Ordinary Share | NO0010734122 | VISTIN PHARMA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.25 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 438.33M | 45.64M | 1.0293 | 10.93 | 498.88M |
From Jun 2023 to Jun 2024
4 July 2023: Vistin Pharma ASA (the “Company”) has on 4 July 2023 sold shares to members of its management team for its long-term incentive plan (LTIP), as approved by the general meeting on the 22 May 2023, at a price of NOK 23,00 per share (the “Purchase Price”).
The following persons discharging managerial responsibilities (primary insiders) have purchased shares:
Kjell-Erik Nordby (CEO): 40 000 shares, each at a price equal to the Purchase PriceAfter this transaction, Kjell-Erik Nordby owns a total of 140 000 shares, corresponding to 0,32% of the share capital and voting rights
Alexander Karlsen (CFO): 50 000 shares, each at a price equal to the Purchase Price After this transaction, Alexander Karlsen owns a total of 50 000 shares, corresponding to 0,11% of the share capital and voting rights
Magnus Tolleshaug (CCO): 40 000 shares, each at a price equal to the Purchase Price After this transaction, Magnus Tolleshaug owns a total of 75 000 shares, corresponding to 0,17% of the share capital and voting rights
Vegard Heggem (VP Operations): 50 000 shares, each at a price equal to the Purchase PriceAfter this transaction, Vegard Heggem owns a total of 77 000 shares, corresponding to 0,17% of the share capital and voting rights
Hilde Merete Hagen (VP Quality): 40 000 shares, each at a price equal to the Purchase PriceAfter this transaction, Hilde Merete Hagen owns a total of 40 000 shares, corresponding to 0,09% of the share capital and voting rights
See attachments for further details.
After these transactions, the Company does not own any own shares.
This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12.
Attachments
1 Year Vistin Pharma Asa Chart |
1 Month Vistin Pharma Asa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
